Gilead Sciences Inc (GILD.O) reported on Friday that additional data from a late-stage study showed that its antiviral remdesivir reduced the risk of death and significantly improved the conditions of severely ill COVID-19 patients. The company, which initially released the data from the trial in April, stated that the finding required confirmation in the clinical trials.
Several countries have approved the use of treatment in severe patients, but there are concerns about the supply of the drug, which is also being tested as an inhaled version. Gilead reported that it analyzed data from 312 patients treated in a late-stage study and a separate real-world retrospective cohort of 818 patients with similar characteristics and disease severity to the study.
Gilead’s late-stage analysis evaluated the safety and efficacy of the 5-day and 10-day dosing durations of remdesivir administered intravenously in hospitalized patients with serious COVID-19 manifestations due to the new coronavirus. The mortality rate for remdesivir-treated patients was 7.6 per cent on Day 14, compared with 12.5 per cent for non-remdesivir-treated patients. Gilead also indicated that the rates and likelihood of recovery were lower in patients receiving hydroxychloroquine and remdesivir compared to patients receiving remdesivir who did not receive hydroxychloroquine.